Tacef

Quick links to important sections

Tacef

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tacef

Property Description
Active Ingredients Ceftriaxone, Tazobactam Sodium Salt
Form Powder for solution for injection or infusion
Pharmacological Class Third-generation Cephalosporin (Antibiotic) and Beta-lactamase inhibitor
Common Use Treatment of systemic bacterial infections
Origin Semisynthetic

Tacef is a powerful semisynthetic fixed-dose combination antibiotic used to resolve serious bacterial infections throughout the body. The drug is commercially known as Tacef (or similar combination products like Montaz and Monotax Xp in certain markets), and its formulation includes a broad-spectrum agent with a unique resistance-defeating component. This medicine is strictly a prescription-only product, reserved for situations where effective microbial clearance is essential.


What Type of Medicine is Tacef? (Identity and Classification)

Pharmacologically, Tacef is categorized as a combination of a Third-generation Cephalosporin and a Beta-lactamase inhibitor. This combination structure defines its primary advantage: the active antibiotic, Ceftriaxone, belongs to the beta-lactam family, known for its ability to kill susceptible organisms by disrupting their cell wall structure. The second component, Tazobactam Sodium Salt, acts as a protective agent, neutralizing the bacterial enzymes, known as beta-lactamases, that would normally destroy the Ceftriaxone, thereby enhancing and preserving its effectiveness. This pairing is clinically recognized for its high efficacy in managing infections caused by resistant bacteria.


Tacef: Composition, Origin, and Form (The Structure)

This medicine is composed of the two core active ingredients, Ceftriaxone and Tazobactam Sodium Salt, and is formulated exclusively as a sterile powder for solution for injection or infusion. It is classified as a semisynthetic compound, meaning it is chemically derived from naturally occurring substances to optimize its therapeutic properties. The use of Tazobactam, a well-known beta-lactamase inhibitor, is incorporated into this clinical application. This specific presentation requires dissolution with a sterile solvent before administration, confirming its identity as a product intended solely for parenteral administration into the bloodstream or muscle, a characteristic typically reserved for the treatment of severe systemic infections in hospitalized patients.


General Purpose: Why is Tacef Used? (High-Level Function)

The general purpose of Tacef is to achieve synergistic and complete elimination of a wide variety of harmful bacteria that cause systemic infection, such as complex abdominal or respiratory infections. By combining the bactericidal strength of Ceftriaxone with the protective mechanism of Tazobactam, the product is engineered to deliver a highly reliable intervention against pathogens, including those exhibiting drug-resistant characteristics, thereby aiding the resolution of severe bacterial challenges.

What side effects are possible with Tacef?

Possible Side Effects and Safety Information

The safety profile for Tacef (Ceftriaxone/Tazobactam) is defined by regulatory documents that classify potential adverse reactions based on their frequency and the system-organ class affected. This framework distinguishes between commonly observed effects and rare, yet serious, reactions.

Commonly Documented Adverse Reactions

The most commonly listed adverse reactions, affecting up to 1 in 10 people, involve gastrointestinal disorders such as diarrhoea, and blood and lymphatic system disorders, including transient changes like eosinophilia, leukopenia, and thrombocytosis. Rash and elevations of hepatic enzymes are also listed as common occurrences. Uncommon effects, affecting up to 1 in 100 people, include headache, dizziness, nausea, and localized reactions such as phlebitis at the injection site.

Serious and Clinically Significant Reactions

Regulatory labeling specifies rare but critical adverse reactions. These include severe allergic responses, such as anaphylactic shock, and severe cutaneous adverse reactions like Stevens-Johnson syndrome (SJS). Issues related to the gastrointestinal system, such as Pseudomembranous colitis (which can occur during or after treatment), are also documented. Neurological events like convulsions and blood disorders such as haemolytic anaemia are reported as not known or rare.

Safety Restrictions and Special Populations

Specific safety restrictions are noted in official labeling. Tacef is strictly contraindicated in hyperbilirubinaemic neonates and premature infants due to the risk of Kernicterus. Furthermore, it must never be administered simultaneously with any calcium-containing intravenous solutions because of the risk of fatal precipitation. A safety note exists for patients with severe renal and hepatic impairment, where a dose limit is typically specified.

Overdose and Emergency Response

The official regulatory documents describing overdose situations for Tacef (Ceftriaxone/Tazobactam) focus on severe outcomes affecting the central nervous system (CNS) and the renal system. Documented clinical manifestations of overdose may include signs of encephalopathy, such as confusion, somnolence, and lethargy, alongside severe events like seizures and non-convulsive status epilepticus. Additionally, high drug concentrations carry a risk of acute renal failure due to the potential formation of urolithiasis (kidney stones).

Specific population constraints are officially noted: patients with severe renal impairment have an increased risk of neurological adverse reactions. For newborns, particularly those who are hyperbilirubinaemic or preterm, there is an explicit warning regarding the risk of bilirubin encephalopathy (kernicterus).

In the event of suspected overdose or the appearance of severe symptoms, immediate emergency action is required. If the individual exhibits signs such as collapse, trouble breathing, or unconsciousness ("can't be awakened"), the governmental guidance mandates calling emergency services at 911. Management is strictly limited to symptomatic and supportive treatment; the official labeling notes that the drug is not reduced by dialysis, confirming the absence of a specific reversal procedure. Contacting the poison control helpline is also a mandated action.

Therapeutic Uses of Tacef

What Tacef Treats: Main Uses and Benefits

This medication is generally considered relevant for treating serious bacterial diseases, including those that may be complex or life-threatening. The medication is commonly used in conditions presenting with systemic or localized discomfort, such as bacterial septicemia, meningitis, complicated urinary tract infections (including pyelonephritis), bone and joint infections, and severe intra-abdominal infections. The combination is commonly used across conditions presenting with acute episodes where the complexity of the infection warrants additional symptomatic support.

Tacef is relevant for managing acute systemic distress, including high, persistent fever, recurrent chills, and symptoms that create noticeable physiological strain. This includes managing symptoms related to systemic imbalance, such as noticeable fever and chills, and symptoms that create noticeable physiological strain, like acute pain and inflammation. The medication provides support that helps ease the overall symptom burden and assists with maintaining functional stability during difficult episodes of heightened physiological stress.

The medication is considered relevant in specific high-risk clinical contexts, particularly within inpatient care, such as providing supportive management for febrile neutropenia or using it as prophylaxis to help prevent infection after certain high-risk surgical procedures. This supports the patient during periods of heightened symptoms when the clinical context involves a significant possibility of severe infection or post-operative complications.

“This therapy is applied in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief to help patients cope more steadily with symptom fluctuations.”


Quick Fact: Relief for Acute Systemic Symptoms

This medication is generally applied in scenarios where additional management of discomfort is required, contributing to improved comfort during periods of heightened symptoms associated with severe bacterial infection.

Regulatory References

  1. Summary Product Characteristics

Eligibility and Restrictions for Use

Who Can and Cannot Use Tacef?

Eligibility for Tacef (Ceftriaxone and Tazobactam combination) is strictly defined by government regulatory documents, determining who is permitted, restricted, or prohibited from using the medicine.

Absolute Contraindications (Must Not Use)

Classification Population Group Rationale (Regulatory Basis)
Contraindicated Patients with known hypersensitivity to Ceftriaxone, Tazobactam, other cephalosporins, penicillins, or any other beta-lactam agents. Risk of severe allergic reaction.
Contraindicated Neonates (le 28 days) who require IV calcium-containing solutions, or who are hyperbilirubinemic. Risk of ceftriaxone-calcium precipitation; risk of kernicterus.
Contraindicated Intravenous use of Tacef solutions prepared with lidocaine. Restricted administration route.

Condition-Based Restrictions

Conditional Use is advised for patients with both hepatic dysfunction and severe renal impairment. For these patients, the daily dosage should not exceed 2 grams of the ceftriaxone component. Caution is also noted for patients with a history of pancreatitis, gallbladder disease, or colitis.

Age-Related Eligibility

Use is generally approved for adults and older children. However, the safety and effectiveness of the combination product are noted in some regulatory contexts as not established in children below two years of age. Dosage adjustment is typically not necessary for older adults (geriatric patients).

Pregnancy and Lactation Status

The medicine should be used during pregnancy only if clearly needed. Use is advised with caution while breastfeeding, as the medication is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official government regulatory documentation outlines specific interaction risks for Tacef, primarily driven by the Ceftriaxone component and the clearance route of the Tazobactam component.

Property Value
Medicinal Product Categories Calcium-containing IV solutions; Renal tubular secretion inhibitors (e.g., Uricosurics); Vitamin K Antagonists; Oral Hormonal Contraceptives.
Specific Interacting Medicines IV calcium solutions, Probenecid, Warfarin, Oral Hormonal Contraceptives, Chloramphenicol.
Mechanistic Basis in Label Physical precipitation; Pharmacokinetic clearance inhibition; Pharmacodynamic enhancement of bleeding; Pharmacodynamic efficacy reduction.

Official Interaction Statements:

  • Co-administration of Tacef with intravenous calcium-containing solutions is formally contraindicated in neonates (le 28 days of age) due to the risk of fatal Ceftriaxone-Calcium precipitate formation.
  • Probenecid causes a reduction in the renal clearance of the Tazobactam component, resulting in increased and prolonged plasma exposure.
  • Tacef may interact pharmacodynamically with Vitamin K antagonists (e.g., Warfarin), requiring the monitoring of coagulation parameters due to the potential for increased bleeding risk.
  • Tacef may reduce the efficacy of oral hormonal contraceptives, necessitating the use of supplementary non-hormonal measures.
  • In non-neonatal patients, Tacef and IV calcium solutions must not be administered simultaneously via the same line; the line must be thoroughly flushed between sequential infusions.
  • Antagonistic effects have been observed in vitro when Ceftriaxone is combined with Chloramphenicol.

Interaction Classifications (High-Level):

The interaction profile is defined by a Contraindicated Combination (IV calcium in neonates), Clinically Significant Pharmacokinetic Interaction (with Probenecid), and Pharmacodynamic Interactions (anticoagulants, oral contraceptives) that require mandatory monitoring or supplementary measures as specified in the official regulatory documents.

Mechanism of Action

How Tacef Works: Mechanism of Action

Tacef operates by targeting the nitric oxide (NO)-cGMP signaling pathway to modulate smooth muscle tone, a core mechanistic domain that shapes its pharmacological response. The overall mechanism is a targeted molecular cascade resulting in localized vasodilation.


Selective Inhibition of the PDE5 Enzyme

Tacef functions as a selective inhibitor of the enzyme phosphodiesterase type 5 (PDE5), which normally breaks down the crucial chemical messenger cyclic guanosine monophosphate (cGMP). By blocking this enzyme, the drug protects and increases the local concentration of cGMP, thereby preserving the signaling activity for smooth muscle relaxation.


Augmentation and Vascular Tone Modulation

The drug's primary action amplifies the natural vasodilatory response initiated by NO release. The sustained elevation of cGMP activates a downstream molecular cascade that leads to the dephosphorylation of key proteins within the smooth muscle cells. This facilitates sustained cGMP presence within the smooth muscle, influencing tone in specific blood vessels and tissues. The resulting relaxation causes vasodilation (widening of blood vessels), characterized by an increase in localized blood flow and a reduction in vascular resistance, consistent with the drug's mechanism of action.

Dosage and Administration Information

How to Use Tacef

Tacef (Ceftriaxone and Tazobactam) is administered exclusively in a supervised clinical setting, as it is supplied only as a sterile powder for solution for injection or infusion. Its official use is restricted to parenteral administration via either a deep intramuscular (IM) injection or a slow intravenous (IV) injection/infusion.


Official Dosing and Frequency

The standard adult daily dose of the Ceftriaxone component typically ranges from 1 g to 2 g. This is generally administered once daily, though the prescribing information allows for divided doses every twelve hours (q12 h) for more severe or complicated infections. The maximum approved daily dose of the Ceftriaxone component must not exceed 4 g. For surgical prophylaxis, a single 1 g IV dose is typically administered shortly before the procedure.

Administration Procedures and Duration

Prior to use, the lyophilized powder must be reconstituted with a specified calcium-free sterile diluent. A critical administration instruction is the absolute restriction against co-administration or mixing of Tacef with any solution that contains calcium, including certain IV fluids. IV infusion must be performed slowly, generally over at least 30 minutes. Treatment duration is typically 4 to 14 days but is guided by the patient's clinical resolution; administration should continue for 48 to 72 hours after the patient is afebrile.


Special Population Rules

For patients with renal or hepatic impairment, the official label explicitly states that no dosage adjustment is necessary for the Ceftriaxone component when the total daily dose is 2 g or less.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tacef

Clinical research on Tacef (Ceftriaxone/Tazobactam) has explored its evaluation in severe infections, particularly those found in hospital settings. The evidence primarily consists of comparative trials, where studies explored the combination against other established, broad-spectrum antibiotic regimens.


Evidence for Severe Urinary and Abdominal Infections

The evidence supporting this combination's evaluation in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI) was evaluated in Randomized Controlled Trials (RCTs). These short-term RCTs research examined hospitalized adults who were experiencing these severe infections.

The trials often employed a non-inferiority design, meaning the regulatory research evaluated whether the combination's outcome was not substantially worse than the established therapy it was compared against. Studies report that the measured results for the combination fell within the pre-defined statistical range of the comparator drugs for both cUTI and cIAI. In cIAI studies, the combination was evaluated in conjunction with an agent providing anaerobic coverage, which means the effect of Tacef alone is not isolated.


Evidence for Severe Respiratory Infections (Pneumonia)

For Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP), the combination was evaluated in dedicated Randomized Controlled Trials (RCTs) focused on critical care settings. The primary endpoints measured included the 28-day all-cause mortality and the overall clinical response rate at the time treatment was completed. Research describes the patterns of measured responses in these critically ill patient populations. Because HABP and VABP are severe conditions, the clinical cure rates observed in these studies were often lower than those observed in trials for less complex infections.


What Remains Uncertain in the Research Landscape

Due to the reliance on the non-inferiority design for most pivotal trials, the research goal was to show the drug was not substantially worse than an established comparator, rather than focusing on superiority. Follow-up durations were limited, meaning the overall research provides context but not individual predictions about long-term recurrence rates. Furthermore, data for certain high-risk groups, such as the frail elderly or those with multiple complex co-existing conditions, remain insufficient for generalized conclusions.

Frequently Asked Questions (FAQ)

Common questions about Tacef (FAQ)

Q: What are the most common side effects people report online for Tacef?

A: The official product information states that the most commonly documented adverse reactions include gastrointestinal issues, such as diarrhoea, and transient changes in blood cell counts. A skin rash is also commonly reported in official sources, representing the types of effects users are most likely to discuss.

Q: Does Tacef make you feel tired or sleepy?

A: Some neurological adverse reactions have been reported in postmarketing surveillance. Official documents note events such as dizziness, somnolence (drowsiness), and lethargy (tiredness). If these effects are experienced, activities requiring alertness should be considered carefully.

Q: Can taking Tacef cause headaches?

A: According to regulatory data, headaches have been reported as an occasional side effect of Tacef. In clinical trials, this was typically observed with a low frequency (less than 1%).

Q: Is it normal to have a slight stomach ache when starting Tacef?

A: While common side effects include general gastrointestinal issues like diarrhoea, the official documentation describes abdominal pain as a rarely observed adverse reaction. Any discomfort should be reported to the prescribing healthcare provider for assessment.

Q: Does Tacef affect your blood pressure?

A: The regulatory documents detailing the safety profile of Tacef do not list high or low blood pressure changes as a commonly documented or clinically significant adverse reaction.

Q: How long do the effects of Tacef last in the body?

A: Official pharmacokinetic data describes how the drug is processed by the body. The elimination half-life for the ceftriaxone component, which is the time it takes for half the drug to be removed, typically ranges from 5.8 to 8.7 hours in healthy adults.

Q: Is Tacef addictive or habit-forming?

A: Tacef is a combination antibiotic used to treat bacterial infections. Regulatory documentation concerning the safety profile of Tacef does not list it as having any known potential for addiction or habit formation.

Q: Can Tacef cause any changes in mood or anxiety levels?

A: Official regulatory documents indicate that some neurological adverse reactions, such as confusion or a disturbance of consciousness, have been reported in postmarketing surveillance. However, changes in mood or anxiety levels are not specifically listed as known side effects.

Q: Are there different strengths or formulations of Tacef?

A: The medicine is supplied as a sterile powder for solution for injection or infusion, which requires preparation before use. It is available in multiple strength combinations of the two active ingredients, Ceftriaxone and Tazobactam.

Q: Does Tacef need to be taken with food, or can it be taken on an empty stomach?

A: Tacef is intended solely for parenteral administration (injection or infusion) and is not a drug taken by mouth. Therefore, instructions regarding taking the medication with or without food do not apply.

Q: Can Tacef cause sun sensitivity or skin rashes?

A: Official product information lists a skin rash as a commonly reported adverse reaction. However, regulatory documents do not specifically list photosensitivity (sun sensitivity) as an adverse event associated with Tacef.

Q: Can Tacef be crushed or split if it is a tablet?

A: Tacef is supplied exclusively as a sterile powder for solution for injection or infusion, not as a tablet or capsule. As a result, questions about crushing or splitting the medicine are not relevant to its administration.

Q: If I miss a dose of Tacef, what happens?

A: Since Tacef is administered on a fixed schedule in a clinical setting, if a dose is missed, it is generally recommended that the healthcare provider or pharmacist be contacted for guidance. The administration schedule is critical for the medicine to work properly.

Q: Can I take Tacef if I am also taking vitamins or supplements?

A: While the primary interaction profiles focus on other drugs, it is standard safety practice for the healthcare provider to be informed about all vitamins, supplements, and other non-prescription products being used.

Q: Does Tacef interact with caffeine or alcohol?

A: Official interaction profiles focus on other drugs. The interaction with alcohol is generally unknown, but caution is often advised as consuming alcohol may potentially increase the risk of certain adverse effects. Caffeine is not specifically mentioned in the official interaction profiles.

Q: Are there any specific foods I should avoid while on Tacef?

A: Regulatory information does not list specific foods that must be avoided while using Tacef. Maintaining generally healthy dietary habits and adequate hydration is a common recommendation while undergoing systemic treatment.

Q: Is Tacef suitable for people who are older (e.g., over 65)?

A: Official product information addresses its use in older adults (geriatric patients). Dosage adjustments are not typically required for these patients, provided they do not have severe, co-existing kidney or liver impairment.

Q: Can Tacef be used by teenagers or children?

A: The medicine is generally approved for use in older children and adolescents. However, some regulatory contexts note that the safety and effectiveness of the combination product have not been established in children below two years of age.

Q: How is Tacef different from an over-the-counter medicine?

A: Tacef is classified as a prescription-only medicine. It is a potent, fixed-dose combination antibiotic reserved for the treatment of severe systemic bacterial infections, which sets it apart from non-prescription, over-the-counter medicines.

Q: What is the total duration of treatment for Tacef?

A: The usual treatment duration for most conditions falls within the range of 4 to 14 days. The total length of therapy is guided by the patient's specific infection and the clinical resolution of symptoms, such as being fever-free for a period.

Q: Are there any known long-term side effects associated with Tacef use?

A: Regulatory documents note that prolonged use of any antibiotic, including Tacef, may result in the overgrowth of non-susceptible organisms (superinfection). Follow-up periods in the initial clinical research studies were often limited, which means information on effects spanning many years is not fully documented.

Q: Why does Tacef need to be taken at a certain time of day?

A: The decision on the frequency of administration (such as once or twice daily) is based on clinical factors. This is determined by the severity and type of infection being treated, and it is guided by the prescriber's clinical judgment.

Q: Will Tacef affect my ability to drive or operate machinery?

A: Official safety advice states that undesirable effects, such as dizziness, may occur during treatment. If dizziness or other neurological effects are experienced, professional advice should be sought regarding activities such as driving or operating machinery.

Q: What happens if I stop taking Tacef suddenly?

A: Treatment is expected to continue for a specific minimum duration to achieve clinical resolution. Stopping prematurely may lead to treatment failure or the overgrowth of non-susceptible organisms (bacteria that are resistant to the medicine).

Q: Why do doctors refer to Tacef by a different name sometimes?

A: Tacef is a brand name for the drug combination. Doctors may refer to the medicine using its generic names, which are Ceftriaxone and Tazobactam. Different brand names may also exist for the same combination in various countries.

Q: Is it true that Tacef is used in combination with other drugs sometimes?

A: Yes, official research indicates that Tacef is sometimes used alongside other medicines. For example, in trials for complex intra-abdominal infections, it was evaluated in conjunction with another agent to provide coverage against anaerobic bacteria.

Q: What happens if I accidentally take two doses of Tacef too close together?

A: If an accidental double dose or over-administration is suspected, it is necessary to contact a healthcare provider or poison control immediately for guidance. This is critical because the medicine is strictly managed.

Q: Is Tacef gluten-free or lactose-free?

A: Because Tacef is formulated as a sterile powder for injection, it is unlikely to contain common food excipients like gluten or lactose. For patients with specific allergies or intolerances, reviewing the product’s full inactive ingredient list is standard practice.

Q: What is the difference between Tacef and its active ingredient?

A: Tacef is the commercial brand name given to the combination product. It contains two distinct active ingredients: the main antibiotic, Ceftriaxone, and a resistance-defeating agent called Tazobactam.

Q: Are there any restrictions on activity while taking Tacef?

A: No general restrictions on physical activity are noted in the official guidance. However, patients should exercise caution regarding activities like driving or operating machinery if they experience undesirable effects such as dizziness.

Q: How is Tacef eliminated from the body?

A: Official pharmacokinetic data explains that the ceftriaxone component is eliminated from the body through two main routes: via the urine (as unchanged drug) and through secretion in the bile (found in the feces).

Q: Does Tacef affect fertility in men or women?

A: Animal reproduction studies with the Tazobactam component found no evidence of impaired fertility. However, it is noted that results from animal studies are not always predictive of human response.

Q: Is the purpose of Tacef purely preventative, or is it a treatment?

A: The official product uses indicate that Tacef serves a dual purpose. It is used for the treatment of established systemic bacterial infections and for pre-operative prophylaxis (prevention) of surgical-site infections in specific circumstances.

Q: Is Tacef a type of antibiotic?

A: Yes, Tacef is classified pharmacologically as a fixed-dose combination antibiotic. It is composed of a third-generation cephalosporin (Ceftriaxone) and a beta-lactamase inhibitor (Tazobactam).

How should Tacef be stored and disposed of?

Storage and Disposal of Tacef (Ceftriaxone and Tazobactam)

The Tacef sterile powder must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from light and moisture. This medication must be kept out of the reach of children and pets.

Stability and Handling

Once reconstituted, the solution's stability is strictly time- and temperature-dependent; consult the full product label for specific in-use time limits. Do not administer Tacef simultaneously with any calcium-containing intravenous solutions due to the risk of precipitation.

Disposal

Unused or expired Tacef must be disposed of according to local, state, and federal regulations. The preferred method is a drug take-back program. Tacef is not on the FDA's flush list and should not be thrown down the drain or toilet. If a take-back program is unavailable, mix the product with an undesirable substance, seal it, and place it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tacef found in:

A-Z Index: